Amarchand, Luthra on record Daiichi $3.2bn block sale of Sun Pharma shares

Tuesday, 28 April 2015 By Prachi Shrivastava Capital Markets

Amarchand Mangaldas’ Mumbai-region and Davis Polk & Wardwell advised Daiichi Sankyo on the $3.2bn sale of its 8.93 per cent stake in Sun Pharmaceutical. Luthra & Luthra and Freshfields Bruckhaus Deringer advised Goldman Sachs which was the sole book runner for the deal.

This deal, which was done by block sale of shares in the open market using the screen-based platform of stock exchanges, is the largest bulk deal on the Indian markets, according to an Amarchand press release.

Amarchand Bangalore partner Nivedita Rao and Davis partner Michael Davis acted for Daiichi.

Luthra Mumbai partner Manan Lahoty and Freshfields Singapore partner Arun Balasubramanian acted for Goldman Sachs.

Last year Sun Pharma had bought debt-ridden pharma giant Ranbaxy from Daiichi for $4bn with Amarchand, Luthra and Crawford Bayley advising.

Amarchand MangaldasLuthra & LuthraDavis Polk & WardwellFreshfields Bruckhaus DeringerL&L Partners

Comments

Wondering 28 Apr 2015, 14:02
+3 -1
Kian- Any idea who instructed Luthra? Its a little weird to see Arun (FF) working alongside Luthra. Don't platinum and FF have best friends relations?
Keep wondering 29 Apr 2015, 10:07
+5 -0
GS instructed Luthra just like it instructed AB@FF. What does best friends have to do with it? No one cares a damn if they are even sworn enemies. Its work and someone is paying for it, simple.
Querist 1 May 2015, 09:42
+1 -0
What happened to P&A Law Offices. Not been retained by Daiichi this time?
good good 1 May 2015, 17:44
+1 -0
Manan and L&L capmarks still as strong as ever!
Commenting is closed for this article.